

-2-

Amendments to the Claims

Please amend Claims 308, 320, 332, 341 and 353-356. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1-150. (Canceled)

151. (Previously presented) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6 and has binding specificity for a chemokine selected from the group consisting of RANTES and MCP-3.
152. (Previously presented) The antibody or antigen-binding fragment of Claim 151, wherein said C-C chemokine receptor 3 protein has binding specificity for RANTES.
153. (Previously presented) The antibody or antigen-binding fragment of Claim 151, wherein said C-C chemokine receptor 3 protein has binding specificity for MCP-3.
154. (Canceled)
155. (Previously presented) The antibody or antigen-binding fragment of Claim 151, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.
156. (Previously presented) The antibody or antigen-binding fragment of Claim 151, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.

-3-

157. (Previously presented) The antibody or antigen-binding fragment of Claim 151, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.
158. (Previously presented) The antibody or antigen-binding fragment of Claim 151, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
159. (Previously presented) The antibody or antigen-binding fragment of Claim 151, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
160. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 151 and a physiologically acceptable vehicle or carrier.
161. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 151.
162. (Previously presented) The isolated cell of Claim 161, wherein said isolated cell is a hybridoma.
163. (Previously presented) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:4 and has binding specificity for a chemokine selected from the group consisting of RANTES and MCP-3.
164. (Previously presented) The antibody or antigen-binding fragment of Claim 163, wherein said C-C chemokine receptor 3 protein has binding specificity for RANTES

08/963,656

-4-

165. (Previously presented) The antibody or antigen-binding fragment of Claim 163, wherein said C-C chemokine receptor 3 protein has binding specificity for MCP-3.
166. (Canceled)
167. (Previously presented) The antibody or antigen-binding fragment of Claim 163, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.
168. (Previously presented) The antibody or antigen-binding fragment of Claim 163, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.
169. (Previously presented) The antibody or antigen-binding fragment of Claim 163, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.
170. (Previously presented) The antibody or antigen-binding fragment of Claim 163, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
171. (Previously presented) The antibody or antigen-binding fragment of Claim 163, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
172. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 163 and a physiologically acceptable vehicle or carrier.

08/963,656

-5-

173. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 163.
174. (Previously presented) The isolated cell of Claim 173, wherein said isolated cell is a hybridoma.
175. (Previously presented) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6 and has binding specificity for eotaxin.
176. (Canceled)
177. (Previously presented) The antibody or antigen-binding fragment of Claim 175, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.
178. (Previously presented) The antibody or antigen-binding fragment of Claim 175, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.
179. (Previously presented) The antibody or antigen-binding fragment of Claim 175, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.
180. (Previously presented) The antibody or antigen-binding fragment of Claim 175, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.

08/963,656

-6-

181. (Previously presented) The antibody or antigen-binding fragment of Claim 175, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
182. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 175 and a physiologically acceptable vehicle or carrier.
183. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 175.
184. (Previously presented) The isolated cell of Claim 183, wherein said isolated cell is a hybridoma.
185. (Previously presented) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:4 and has binding specificity for eotaxin.
186. (Canceled)
187. (Previously presented) The antibody or antigen-binding fragment of Claim 185, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:4.
188. (Previously presented) The antibody or antigen-binding fragment of Claim 185, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.

08/963,656

-7-

189. (Previously presented) The antibody or antigen-binding fragment of Claim 185, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
190. (Previously presented) The antibody or antigen-binding fragment of Claim 185, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
191. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 185 and a physiologically acceptable vehicle or carrier.
192. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 185.
193. (Previously presented) The isolated cell of Claim 192, wherein said isolated cell is a hybridoma.
194. (Previously presented) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6 and has binding specificity for a chemokine selected from the group consisting of MCP-2 and MCP-4.
195. (Canceled)
196. (Previously presented) The antibody or antigen-binding fragment of Claim 194, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.

08/963,656

-8-

197. (Previously presented) The antibody or antigen-binding fragment of Claim 194, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.
198. (Previously presented) The antibody or antigen-binding fragment of Claim 194, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.
199. (Previously presented) The antibody or antigen-binding fragment of Claim 194, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
200. (Previously presented) The antibody or antigen-binding fragment of Claim 194, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
201. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 194 and a physiologically acceptable vehicle or carrier.
202. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 194.
203. (Previously presented) The isolated cell of Claim 202, wherein said isolated cell is a hybridoma.
204. (Previously presented) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:4 and has binding specificity for a chemokine selected from the group consisting of MCP-2 and MCP-4.

08/963,656

-9-

205. (Previously presented) The antibody or antigen-binding fragment of Claim 204, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said C-C chemokine receptor 3 protein.
206. (Previously presented) The antibody or antigen-binding fragment of Claim 204, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:4.
207. (Previously presented) The antibody or antigen-binding fragment of Claim 204, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.
208. (Previously presented) The antibody or antigen-binding fragment of Claim 204, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
209. (Previously presented) The antibody or antigen-binding fragment of Claim 204, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
210. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 204 and a physiologically acceptable vehicle or carrier.
211. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 204.
212. (Previously presented) The isolated cell of Claim 211, wherein said isolated cell is a hybridoma.

08/963,656

-10-

213. (Previously presented) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein comprises the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:6.
214. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 213 and a physiologically acceptable vehicle or carrier.
215. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 213.
216. (Previously presented) The isolated cell of Claim 215, wherein said isolated cell is a hybridoma.
217. (Previously presented) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein comprises the amino acid sequence of SEQ ID NO:4.
218. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 217 and a physiologically acceptable vehicle or carrier.
219. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 217.
220. (Previously presented) The isolated cell of Claim 219, wherein said isolated cell is a hybridoma.
- 221-245. (Canceled)
246. (Previously presented) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C

08/963,656

-11-

chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of the complement of SEQ ID NO: 1 or the complement of SEQ ID NO:5 under hybridization conditions of 50% formamide, 5X SSC, 1X Denhardt's solution, 10% dextran sulfate, 20 mM Tris(hydroxymethyl)aminomethane pH 7.5 and 1% SDS at 42°C, and wash conditions of 2X SSC/0.1% SDS at 42°C, and has binding specificity for eotaxin.

247. (Canceled)

248. (Previously presented) The antibody or antigen-binding fragment of Claim 246, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.

249. (Previously presented) The antibody or antigen-binding fragment of Claim 246, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.

250. (Previously presented) The antibody or antigen-binding fragment of Claim 246, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.

251. (Previously presented) The antibody or antigen-binding fragment of Claim 246, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.

252. (Previously presented) The antibody or antigen-binding fragment of Claim 246, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.

08/963,656

-12-

253. (Previously presented) The antibody or antigen-binding fragment of Claim 246, wherein said C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of the complement of SEQ ID NO:1 or the complement of SEQ ID NO:5 under hybridization conditions of 6X SSC containing 5X Denhardt's solution, 10% (w/v) dextran sulfate, 2% SDS and sheared salmon sperm DNA (100 µg/mL) at 65°C and wash conditions of 0.2X SSC, 0.5% SDS at 65°C, and has binding specificity for eotaxin.
254. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 246 and a physiologically acceptable vehicle or carrier.
255. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 246.
256. (Previously presented) The isolated cell of Claim 255, wherein said isolated cell is a hybridoma.
257. (Previously presented) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of the complement of SEQ ID NO:3 under hybridization conditions of 50% formamide, 5X SSC, 1X Denhardt's solution, 10% dextran sulfate, 20 mM Tris(hydroxymethyl)aminomethane pH 7.5 and 1% SDS at 42°C, and wash conditions of 2X SSC/0.1% SDS at 42°C, and has binding specificity for eotaxin.
258. (Canceled)
259. (Previously presented) The antibody or antigen-binding fragment of Claim 257, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein

08/963,656

-13-

comprising the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:4.

260. (Previously presented) The antibody or antigen-binding fragment of Claim 257, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.
261. (Previously presented) The antibody or antigen-binding fragment of Claim 257, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
262. (Previously presented) The antibody or antigen-binding fragment of Claim 257, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
263. (Previously presented) The antibody or antigen-binding fragment of Claim 257, wherein said C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of the complement of SEQ ID NO:3 under hybridization conditions of 6X SSC containing 5X Denhardt's solution, 10% (w/v) dextran sulfate, 2% SDS and sheared salmon sperm DNA (100 µg/mL) at 65°C and wash conditions of 0.2X SSC, 0.5% SDS at 65°C, and has binding specificity for eotaxin.
264. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 257 and a physiologically acceptable vehicle or carrier.
265. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 257.
266. (Previously presented) The isolated cell of Claim 265, wherein said isolated cell is a hybridoma.

08/963,656

-14-

267-291. (Canceled)

292. (Previously presented) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein is encoded by SEQ ID NO:1 or SEQ ID NO:5.
293. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 292 and a physiologically acceptable vehicle or carrier.
294. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 292.
295. (Previously presented) The isolated cell of Claim 294, wherein said isolated cell is a hybridoma.
296. (Previously presented) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein is encoded by SEQ ID NO:3.
297. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 296 and a physiologically acceptable vehicle or carrier.
298. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 296.
299. (Previously presented) The isolated cell of Claim 298, wherein said isolated cell is a hybridoma.
300. (Previously presented) Antibody 7B11 (ATCC Accession No. HB-12195) or an antigen-binding fragment thereof.

-15-

301. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 300 and a physiologically acceptable vehicle or carrier.
302. (Previously presented) The hybridoma cell line deposited under ATCC Accession No. HB-12195.
303. (Previously presented) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3, wherein said antibody or antigen-binding fragment comprises the light chain CDRs (CDR1, CDR2 and CDR3) and the heavy chain CDRs (CDR1, CDR2 and CDR3) of monoclonal antibody 7B11 (ATCC Accession No. HB-12195).
304. (Previously presented) The antibody or antigen-binding fragment of Claim 303 wherein said antibody or fragment is a humanized immunoglobulin or antigen-binding fragment thereof comprising the light chain CDRs (CDR1, CDR2 and CDR3) and the heavy chain CDRs (CDR1, CDR2 and CDR3) of monoclonal antibody 7B11 (ATCC Accession No. HB-12195) and a human framework region.
305. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 303 and a physiologically acceptable vehicle or carrier.
306. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 303.
307. (Previously presented) The isolated cell of Claim 306, wherein said isolated cell is a hybridoma.
308. (Currently amended) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3 protein, wherein said antibody or antigen-binding fragment binds a C-C chemokine receptor 3 protein that is expressed on the surface of [[a]] an intact cell, and wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6 and has

-16-

binding specificity for a chemokine selected from the group consisting of RANTES and MCP-3.

309. (Previously presented) The antibody or antigen-binding fragment of Claim 308, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said C-C chemokine receptor 3 protein.
310. (Previously presented) The antibody or antigen-binding fragment of Claim 309, wherein said ligand is selected from the group consisting of RANTES and MCP-3.
311. (Previously presented) The antibody or antigen-binding fragment of Claim 308, wherein said C-C chemokine receptor 3 protein comprises SEQ ID NO:2.
312. (Previously presented) The antibody or antigen-binding fragment of Claim 308, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.
313. (Previously presented) The antibody or antigen-binding fragment of Claim 308, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.
314. (Previously presented) The antibody or antigen-binding fragment of Claim 308, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.
315. (Previously presented) The antibody or antigen-binding fragment of Claim 308, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.

08/963,656

-17-

316. (Previously presented) The antibody or antigen-binding fragment of Claim 308, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
317. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 308 and a physiologically acceptable vehicle or carrier.
318. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 308.
319. (Previously presented) The isolated cell of Claim 318, wherein said isolated cell is a hybridoma.
320. (Currently amended) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3, wherein said antibody or antigen-binding fragment binds a C-C chemokine receptor 3 protein that is expressed on the surface of [[a]] an intact cell, and wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6 and has binding specificity for eotaxin.
321. (Previously presented) The antibody or antigen-binding fragment of Claim 320, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said C-C chemokine receptor 3 protein.
322. (Previously presented) The antibody or antigen-binding fragment of Claim 321, wherein said ligand is selected from the group consisting of RANTES, MCP-3 and eotaxin.
323. (Previously presented) The antibody or antigen-binding fragment of Claim 320, wherein said C-C chemokine receptor 3 protein comprises SEQ ID NO:2.

-18-

324. (Previously presented) The antibody or antigen-binding fragment of Claim 320, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.
325. (Previously presented) The antibody or antigen-binding fragment of Claim 320, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.
326. (Previously presented) The antibody or antigen-binding fragment of Claim 320, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.
327. (Previously presented) The antibody or antigen-binding fragment of Claim 320, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
328. (Previously presented) The antibody or antigen-binding fragment of Claim 320, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
329. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 320 and a physiologically acceptable vehicle or carrier.
330. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 320.
331. (Previously presented) The isolated cell of Claim 330, wherein said isolated cell is a hybridoma.

-19-

332. (Currently amended) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3 protein, wherein said antibody or antigen-binding fragment binds a C-C chemokine receptor 3 protein that is expressed on the surface of [[a]] an intact cell, and wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6 and has binding specificity for a chemokine selected from the group consisting of MCP-2 and MCP-4.
333. (Previously presented) The antibody or antigen-binding fragment of Claim 332, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said C-C chemokine receptor 3 protein.
334. (Previously presented) The antibody or antigen-binding fragment of Claim 333, wherein said ligand is selected from the group consisting of RANTES, MCP-3, eotaxin, MCP-2 and MCP-4.
335. (Previously presented) The antibody or antigen-binding fragment of Claim 332, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.
336. (Previously presented) The antibody or antigen-binding fragment of Claim 332, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
337. (Previously presented) The antibody or antigen-binding fragment of Claim 332, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
338. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 332 and a physiologically acceptable vehicle or carrier.

-20-

339. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 332.
340. (Previously presented) The isolated cell of Claim 339, wherein said isolated cell is a hybridoma.
341. (Currently amended) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3, wherein said antibody or antigen-binding fragment binds a C-C chemokine receptor 3 protein that is expressed on the surface of [[a]] an intact cell, and wherein said C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of the complement of SEQ ID NO: 1 or the complement of SEQ ID NO:5 under hybridization conditions of 50% formamide, 5X SSC, 1X Denhardt's solution, 10% dextran sulfate, 20 mM Tris(hydroxymethyl)aminomethane pH 7.5 and 1% SDS at 42°C, and wash conditions of 2X SSC/0.1% SDS at 42°C, and has binding specificity for eotaxin.
342. (Previously presented) The antibody or antigen-binding fragment of Claim 341, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said C-C chemokine receptor 3 protein.
343. (Previously presented) The antibody or antigen-binding fragment of Claim 342, wherein said ligand is selected from the group consisting of RANTES, MCP-3 and eotaxin.
344. (Previously presented) The antibody or antigen-binding fragment of Claim 341, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.
345. (Previously presented) The antibody or antigen-binding fragment of Claim 341, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11

-21-

(ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.

346. (Previously presented) The antibody or antigen-binding fragment of Claim 341, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.
347. (Previously presented) The antibody or antigen-binding fragment of Claim 341, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
348. (Previously presented) The antibody or antigen-binding fragment of Claim 341, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.
349. (Previously presented) The antibody or antigen-binding fragment of Claim 341, wherein said C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of the complement of SEQ ID NO:1 or the complement of SEQ ID NO:5 under hybridization conditions of 6X SSC containing 5X Denhardt's solution, 10% (w/v) dextran sulfate, 2% SDS and sheared salmon sperm DNA (100 µg/mL) at 65°C and wash conditions of 0.2X SSC, 0.5% SDS at 65°C, and has binding specificity for eotaxin.
350. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 341 and a physiologically acceptable vehicle or carrier.
351. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 341.
352. (Previously presented) The isolated cell of Claim 351, wherein said isolated cell is a hybridoma.

-22-

353. (Currently amended) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3 protein, wherein said antibody or antigen-binding fragment binds a C-C chemokine receptor 3 protein that is expressed on the surface of [[a]] an intact cell, and wherein said C-C chemokine receptor 3 protein comprises the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:6.
354. (Currently amended) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3 protein, wherein said antibody or antigen-binding fragment binds a C-C chemokine receptor 3 protein that is expressed on the surface of [[a]] an intact cell, and wherein said C-C chemokine receptor 3 protein comprises the amino acid sequence of SEQ ID NO:4.
355. (Currently amended) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3 protein, wherein said antibody or antigen-binding fragment binds a C-C chemokine receptor 3 protein that is expressed on the surface of [[a]] an intact cell, and wherein said C-C chemokine receptor 3 protein is encoded by SEQ ID NO:1 or SEQ ID NO:5.
356. (Currently amended) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3 protein, wherein said antibody or antigen-binding fragment binds a C-C chemokine receptor 3 protein that is expressed on the surface of [[a]] an intact cell, and wherein said C-C chemokine receptor 3 protein is encoded by SEQ ID NO:3.